Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1311 participants
OBSERVATIONAL
2013-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Asia Pacific and Russia Diagnostic Study for EGFR Testing
NCT01788163
Retrospective Study in a NSCLC M+ p
NCT01795352
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
NCT03562819
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
NCT04912687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Locally advanced/metastatic NSCLC pts.
Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not suitable for curative treatment or metastatic (stage IV) NSCLC.
* Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are systemic treatment Naïve (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent disease who have previously received adjuvant chemotherapy (not including EGFR-TKI)
* Provision of diagnostic cancer tissue or cytology sample upon inclusion
* Provision of a routine blood sample
Exclusion Criteria
* Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study
* Pregnancy or breast-feeding
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rose McCormack, PhD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Saint-Quentin, , France
Research Site
Villefranche-sur-Saône, , France
Research Site
Buch, , Germany
Research Site
Großhansdorf, , Germany
Research Site
Compiègne, , France
Research Site
Gap, , France
Research Site
Le Mans, , France
Research Site
Longjumeau, , France
Research Site
Meaux, , France
Research Site
Saint-Brieuc, , France
Research Site
Saint-Michel, , France
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hemer, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Löwenstein, , Germany
Research Site
Münnerstadt, , Germany
Research Site
Nuremberg, , Germany
Research Site
Solingen, , Germany
Research Site
Bari, , Italy
Research Site
Bologna, , Italy
Research Site
Lecce, , Italy
Research Site
Monza, , Italy
Research Site
Napoli, , Italy
Research Site
Orbassano (TO), , Italy
Research Site
Perugia, , Italy
Research Site
Rome, , Italy
Research Site
Hirakata, , Japan
Research Site
Iizuka, , Japan
Research Site
Kanazawa, , Japan
Research Site
Mibu, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nagoya, , Japan
Research Site
Tokyo, , Japan
Research Site
Toyonaka, , Japan
Research Site
's-Hertogenbosch, , Netherlands
Research Site
Arnhem, , Netherlands
Research Site
Bergen op Zoom, , Netherlands
Research Site
Breda, , Netherlands
Research Site
Nieuwegein, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Barcelona, , Spain
Research Site
Burgos, , Spain
Research Site
Cruces, , Spain
Research Site
Donostia / San Sebastian, , Spain
Research Site
León, , Spain
Research Site
Madrid, , Spain
Research Site
Pontevedra, , Spain
Research Site
Gävle, , Sweden
Research Site
Karlstad, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Cardiff, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D7913C00070
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.